Healthcare
MeiraGTx Holdings plc(MGTX)
Live Price
Offline$11.32
+8.74% today
1Y Change
+80.58%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $870.00M
- Revenue Growth
- +144.6%
- EPS Growth
- +33.0%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
MeiraGTx Holdings plc (MGTX) is a Healthcare stock with a market cap of $870.00M and listed on NASDAQ. The stock last traded around $11.32 and up 80.6% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +144.6%, EPS growth of +33.0%, a dividend yield of 0.0%. What stands out right now is revenue +144.6%, EPS +33.0%, free cash flow +54.1% with operating margin -130.2% and ROIC -70.9%. Valuation already assumes a fairly strong business story at price/sales 10.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines MGTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+144.6% vs +7.6% peer median
Operating Margin
Below sector median
-130.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +144.6% and EPS at +33.0%, with operating margin around -130.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +1.8% | -6.7% | -6.6% |
2026 Mar 26, 2026 | +131.7% | +1.2% | +21.9% | +22.6% |
2025 Nov 13, 2025 | -24.0% | -0.8% | -10.0% | +8.0% |
Benchmark Edge
MGTX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MGTX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MGTX Max Drawdown
-24.51%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MGTX and SPY.
Company Overview
MeiraGTx Holdings plc
NASDAQ Global Select
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
- Leadership
- Alexandria Forbes
- IPO Date
- Jun 8, 2018
- Employees
- 375
- Street Address
- 430 East 29th Street
- Mailing
- New York City, NY, 10016
- Region
- New York City, NY, US
- Reporting Currency
- USD
- Investor Line
- 646 860 7985
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 10.7
- Price/Book
- โ
Growth
- Revenue
- +144.6%
- EPS
- +33.0%
- Free Cash Flow
- +54.1%
Profitability
- Gross Margin
- 94.0%
- Operating Margin
- -130.2%
- Net Margin
- -140.3%
- ROE
- 4438.9%
- ROIC
- -70.9%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.75
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.